CervoMed Inc. Payments to Acquire Marketable Securities
CervoMed Inc. (CRVO) reported Payments to Acquire Marketable Securities of $3.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-07
- CervoMed Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $2.47M, a 74.64% decline year-over-year.
- CervoMed Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $989.18K, a 86.07% decline year-over-year.
- CervoMed Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $4.63M, a 27.33% increase year-over-year.
- CervoMed Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $3.92M, a 0.53% increase year-over-year.
- CervoMed Inc. payments to acquire marketable securities for fiscal 2025 was $25.40M, a 47.19% decline from fiscal 2024.
- CervoMed Inc. payments to acquire marketable securities for fiscal 2024 was $48.10M.
- CervoMed Inc. payments to acquire marketable securities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CervoMed Inc. payments to acquire marketable securities for fiscal 2022 was $37.99M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $3.46M 10-Q · filed 2026-08-07 | $8.09M derived: sum of 3 quarters · filed 2026-08-07 | $12.01M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $989.18K 10-Q · filed 2026-05-15 | $5.62M derived: sum of 2 quarters · filed 2026-05-15 | $9.53M derived: sum of 3 quarters · filed 2026-05-15 | $19.29M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $8.54M derived: sum of 2 quarters · filed 2026-03-13 | $18.30M derived: sum of 3 quarters · filed 2026-08-07 | $25.40M 10-K · filed 2026-03-13 |
| 2025-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $13.67M derived: sum of 2 quarters · filed 2026-08-07 | $20.78M 10-Q · filed 2025-11-07 | $24.41M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $9.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $16.86M 10-Q · filed 2026-08-07 | $20.49M derived: sum of 3 quarters · filed 2026-08-07 | $24.39M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $7.10M 10-Q · filed 2026-05-15 | $10.74M derived: sum of 2 quarters · filed 2026-05-15 | $14.63M derived: sum of 3 quarters · filed 2026-05-15 | $55.20M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $7.53M derived: sum of 2 quarters · filed 2026-03-13 | $48.10M derived: sum of 3 quarters · filed 2026-03-13 | $48.10M 10-K · filed 2026-03-13 |
| 2024-09-30 | $3.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $44.47M derived: sum of 2 quarters · filed 2025-11-07 | $44.47M 10-Q · filed 2025-11-07 | $44.47M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $40.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $40.57M 10-Q · filed 2025-08-08 | $40.57M derived: sum of 3 quarters · filed 2025-08-08 | $40.57M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2025-05-12 | $0.00 derived: sum of 3 quarters · filed 2025-05-12 | $0.00 derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $0.00 derived: sum of 3 quarters · filed 2025-03-17 | $0.00 10-K · filed 2025-03-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 3 quarters · filed 2024-08-09 | $6.37M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | $6.37M derived: sum of 3 quarters · filed 2023-05-15 | $15.27M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $6.37M derived: sum of 2 quarters · filed 2023-03-24 | $15.27M derived: sum of 3 quarters · filed 2023-08-08 | $37.99M 10-K · filed 2023-03-24 |
| 2022-09-30 | $6.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $15.27M derived: sum of 2 quarters · filed 2023-08-08 | $37.99M 10-Q · filed 2022-11-14 | $37.99M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-06-30 | $8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $31.62M 10-Q · filed 2023-08-08 | $31.62M derived: sum of 3 quarters · filed 2023-08-08 | $31.62M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $22.72M 10-Q · filed 2023-05-15 | $22.72M derived: sum of 2 quarters · filed 2023-05-15 | $22.72M derived: sum of 3 quarters · filed 2023-05-15 | $22.72M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $0.00 derived: sum of 3 quarters · filed 2023-03-24 | $0.00 10-K · filed 2023-03-24 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |